C型慢性肝炎治療薬「ソブリアードカプセル100mg」に関し安全性速報（ブルーレター）を発出しました｜厚生労働省
https://www.mhlw.go.jp/stf/houdou/0000062032.htmlC型慢性肝炎治療薬「ソブリアードカプセル100mg」に関し安全性速報（ブルーレター）を発出しました｜厚生労働省
Open the dedicated viewer to inspect the saved page with archive metadata pinned above it, similar to archive wrappers such as Web Gyotaku.
This is a self-contained HTML copy with CSS and images embedded, so it still renders even if the original page disappears.
The dedicated viewer keeps the original URL and saved timestamp visible while you review the archived HTML.
This page announces that the Ministry of Health, Labour and Welfare has issued a safety alert regarding the hepatitis C antiviral drug "Sobriard Capsule 100mg" due to reported deaths related to elevated bilirubin levels. Following three domestic fatality cases causally linked to the drug, the product labeling has been revised and healthcare providers have been instructed to provide immediate warnings. Key measures include regular blood bilirubin monitoring during treatment, discontinuation if abnormalities occur, continued observation after treatment cessation, and patient guidance to seek immediate medical consultation if symptoms such as jaundice or dark urine appear.
